Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County COVID Drug Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Coronavirus 19 (COVID-19) Anti-Stockpiling Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity limits and prior-authorization overrides for chloroquine, hydroxychloroquine, and lopinavir/ritonavir products used for COVID-19, malaria prophylaxis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, or HIV-1 infection.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCoronavirus 19 (COVID-19) Anti-Stockpiling Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2020
    Next Review DateN/A
    Key ActionSubmit the clinical indication and requested quantity when requesting medication beyond the standard one-episode COVID-19 allowance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    365 daysCOVID-19 allowance period
    56 tabletsChloroquine 250 mg allowance
    28 tabletsChloroquine 500 mg/Plaquenil allowance
    160 mLKaletra oral solution allowance

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 tablets/30 days
    Plaquenil rheumatologic therapy

    Medication-Specific Coverage Criteria

    Chloroquine 250 mg tablets

    Coverage may be approved when ANY of the following applies.

    Applicable coverage pathway

    • Additional COVID-19 episode: The patient needs treatment for an additional episode of Coronavirus 2019 (COVID-19) within a 365-day period.One-time override of 56 tablets
    • Malaria prophylaxis: The patient needs malaria prophylaxis therapy before, during, and after travel to a malaria-endemic area.Quantity sufficient for up to 500 mg (2 tablets) weekly for 2 weeks before entering the endemic area, during the stay, and for 8 weeks after return

    Chloroquine 500 mg tablets

    Coverage may be approved when ANY of the following applies.

    Applicable coverage pathway

    • Additional COVID-19 episode: The patient needs treatment for an additional episode of Coronavirus 2019 (COVID-19) within a 365-day period.One-time override of 28 tablets
    • Malaria prophylaxis: The patient needs malaria prophylaxis therapy before, during, and after travel to a malaria-endemic area.Quantity sufficient for up to 500 mg (1 tablet) weekly for 2 weeks before entering the endemic area, during the stay, and for 8 weeks after return

    Plaquenil 200 mg tablets

    Coverage may be approved when ANY of the following applies.

    Applicable coverage pathway

    • Additional COVID-19 episode: The patient needs treatment for an additional episode of Coronavirus 2019 (COVID-19) within a 365-day period.One-time override of 28 tablets
    • Malaria prophylaxis: The patient needs malaria prophylaxis therapy before, during, and after travel to a malaria-endemic area.Quantity sufficient for up to 400 mg (2 tablets) weekly for 2 weeks before entering the endemic area, during the stay, and for 4 weeks after return
    • Chronic rheumatologic disease: The patient has rheumatoid arthritis, systemic lupus erythematosus, or lupus nephritis.Up to 90 tablets per 30 days for 12 months

    Kaletra tablets and oral solution

    Coverage may be approved when ANY of the following applies.

    Applicable coverage pathway

    • Additional COVID-19 episode: The patient needs treatment for an additional episode of Coronavirus 2019 (COVID-19) within a 365-day period.One-time override: 56 tablets for Kaletra 200/50 mg, 112 tablets for Kaletra 100/25 mg, or 160 mL (1 bottle) for Kaletra 80/20 mg per mL oral solution
    • HIV-1 treatment: The patient is using Kaletra for the treatment of HIV-1 infection.Approve the requested amount

    Initial or Additional Therapy

    Indication-specific initial authorization

    Initial or additional therapy may be approved when ANY of the following indication-specific criteria applies.

    Indication-specific approval

    • Additional COVID-19 episode: The patient needs treatment for an additional episode of Coronavirus 2019 (COVID-19) within a 365-day period.One-time override limited by product strength: 56 chloroquine 250 mg tablets, 28 chloroquine 500 mg tablets, 28 Plaquenil 200 mg tablets, 56 Kaletra 200/50 mg tablets, 112 Kaletra 100/25 mg tablets, or 160 mL (1 bottle) of Kaletra 80/20 mg per mL oral solution
    • Malaria prophylaxis: The patient needs malaria prophylaxis therapy before, during, and after travel to a malaria-endemic area.Quantity sufficient for the applicable pre-travel, travel, and post-travel regimen

    Continuation Therapy

    Plaquenil continuation for rheumatologic disease

    Continuation coverage may be approved when the following criterion is met.

    Hydroxychloroquine chronic therapy: The patient has rheumatoid arthritis, systemic lupus erythematosus, or lupus nephritis.Up to 90 tablets per 30 days for 12 months

    Standard Medication Allowances

    Quantity limit
    MedicationChloroquine 250 mg tablets
    Standard quantity limit56 tablets
    Allowance periodOne 365-day period
    Quantity limit
    MedicationChloroquine 500 mg tablets
    Standard quantity limit28 tablets
    Allowance periodOne 365-day period

    Prior Authorization and Override Requirements

    Prior Authorization

    Additional Medication Requires Prior Authorization

    Coverage of medication beyond the amount provided to treat one COVID-19 episode in a 365-day period requires prior authorization.

    • Submit a prior authorization request for additional medication beyond the one-episode allowance.
    Prior Authorization

    Chloroquine 250 mg COVID-19 Override

    For an additional COVID-19 episode within the same 365-day period, request a one-time override of 56 chloroquine 250 mg tablets. Chloroquine may also be approved for malaria prophylaxis in the quantity needed for the specified dosing schedule.

    • Additional COVID-19 episode: one-time override of 56 tablets.
    • Malaria prophylaxis: up to 500 mg (2 tablets) weekly for 2 weeks before travel, during the stay in the endemic area, and for 8 weeks after return.

    Policy Background

    The covered medications—chloroquine, hydroxychloroquine (Plaquenil), and lopinavir/ritonavir (Kaletra)—have approved uses for parasitic diseases, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and HIV-1 infection. Clinical evidence also supports use of these medications in the treatment of COVID-19.

    The policy provides medication for one COVID-19 episode within a 365-day period and requires prior authorization for additional medication. These controls are intended to preserve access for indicated treatment while preventing stockpiling, misuse, and overuse.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCoronavirus 19 (COVID-19) Anti-Stockpiling Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2020
    Next Review DateN/A
    Key ActionSubmit the clinical indication and requested quantity when requesting medication beyond the standard one-episode COVID-19 allowance.
    SourceLink
    On This Page
    Medication-Specific Coverage CriteriaInitial or Additional TherapyContinuation TherapyStandard Medication AllowancesPrior Authorization and Override RequirementsPolicy Background
    RA, SLE, or lupus nephritis: The patient has rheumatoid arthritis, systemic lupus erythematosus, or lupus nephritis and is requesting Plaquenil.Up to 90 tablets per 30 days for 12 months
  1. HIV-1 infection: The patient is using Kaletra for treatment of HIV-1 infection.Approve the requested amount
  2. Quantity limit
    MedicationPlaquenil (hydroxychloroquine) 200 mg tablets
    Standard quantity limit28 tablets
    Allowance periodOne 365-day period
    Quantity limit
    MedicationKaletra 200 mg/50 mg tablets
    Standard quantity limit56 tablets
    Allowance periodOne 365-day period
    Quantity limit
    MedicationKaletra 100 mg/25 mg tablets
    Standard quantity limit112 tablets
    Allowance periodOne 365-day period
    Quantity limit
    MedicationKaletra 80 mg/20 mg/mL oral solution
    Standard quantity limit160 mL (1 bottle)
    Allowance periodOne 365-day period
    Prior Authorization

    Chloroquine 500 mg COVID-19 Override

    For an additional COVID-19 episode within the same 365-day period, request a one-time override of 28 chloroquine 500 mg tablets. Chloroquine may also be approved for malaria prophylaxis in the quantity needed for the specified dosing schedule.

    • Additional COVID-19 episode: one-time override of 28 tablets.
    • Malaria prophylaxis: up to 500 mg (1 tablet) weekly for 2 weeks before travel, during the stay in the endemic area, and for 8 weeks after return.
    Prior Authorization

    Hydroxychloroquine Overrides

    For Plaquenil (hydroxychloroquine) 200 mg tablets, a one-time override of 28 tablets may be approved for an additional COVID-19 episode within the same 365-day period. Additional quantities may be approved for malaria prophylaxis or covered rheumatologic disease.

    • Additional COVID-19 episode: one-time override of 28 tablets.
    • Malaria prophylaxis: up to 400 mg (2 tablets) weekly for 2 weeks before travel, during the stay in the endemic area, and for 4 weeks after return.
    • Rheumatoid arthritis, systemic lupus erythematosus, or lupus nephritis: up to 90 tablets per 30 days for 12 months.
    Prior Authorization

    Kaletra Overrides and HIV-1 Treatment

    Kaletra overrides may be approved for an additional COVID-19 episode within the same 365-day period. For HIV-1 treatment, approve the requested amount for the applicable formulation.

    • Kaletra 200/50 mg tablets: one-time COVID-19 override of 56 tablets.
    • Kaletra 100/25 mg tablets: one-time COVID-19 override of 112 tablets.
    • Kaletra 80/20 mg/mL oral solution: one-time COVID-19 override of 160 mL (1 bottle).
    • For HIV-1 infection, approve the requested amount for any listed Kaletra formulation.
    Documentation Required

    Indication and Quantity Documentation

    Document the clinical indication and the quantity requested when seeking an override or additional medication. Documentation must support the additional COVID-19 episode or another covered indication, such as malaria prophylaxis, rheumatologic disease, or HIV-1 treatment.

    • Identify the medication, strength or formulation, clinical indication, and requested quantity.
    • For an additional COVID-19 episode, document that the request is for treatment of an additional episode within the same 365-day period.
    • For malaria prophylaxis, document the planned travel and dosing period.
    • For hydroxychloroquine, document rheumatoid arthritis, systemic lupus erythematosus, or lupus nephritis when applicable.
    • For Kaletra, document HIV-1 infection when requesting the requested treatment amount.
    Denial Risk

    Exceeds Annual COVID-19 Allowance

    The policy provides medication to treat one COVID-19 episode in a 365-day period. Requests exceeding the annual allowance are not automatically covered and require prior authorization; unsupported requests may be denied.

    • Annual COVID-19 allowance: one episode per 365-day period.
    • Standard quantities include 56 chloroquine 250 mg tablets, 28 chloroquine 500 mg tablets, 28 hydroxychloroquine 200 mg tablets, 56 Kaletra 200/50 mg tablets, 112 Kaletra 100/25 mg tablets, or 160 mL (1 bottle) of Kaletra oral solution.
    • Obtain authorization before dispensing quantities that exceed the applicable allowance.